美股市場個股詳情
YMAB Y-mAbs Therapeutics
- 8.280
- -0.290-3.38%
收盤價 12/20 16:00 (美東)
- 8.280
- 0.0000.00%
盤後 16:20 (美東)
3.71億總市值-15.33市盈率TTM
8.500最高價7.996最低價114.30萬股成交量8.470今開8.570昨收945.26萬成交額4.22%換手率虧損市盈率(靜)4478.91萬總股本20.90052周最高4.01市淨率2.24億流通值6.48052周最低--股息TTM2707.46萬流通股55.215歷史最高--股息率TTM5.88%振幅2.700歷史最低8.269平均價1股每手
關於Y-mAbs Therapeutics公司
Y-mAbs Therapeutics Inc 是一家商業化階段的生物製藥公司。該公司主要從事用於治療癌症的新型抗體治療產品的開發和商業化。DANYELZA 是該公司第一個獲得 FDA 批准的產品，它是一種重組人源化免疫球蛋白 G，1k 亞型，或稱 IgG1k 單克隆抗體或 mAb，靶向神經節苷脂 GD2。
公司介紹
公司代碼YMAB
公司名稱Y-mAbs Therapeutics
上市日期2018/09/21
發行價格16.00
成立日期2015
CEOMr. Michael Rossi
所屬市場納斯達克
員工數量100
年結日12-31
公司地址230 Park Avenue,Suite 3350
城市New York
省份紐約州
國家美國
郵編10169-0005
電話1-646-885-8505
董事高管
- 姓名
- 職務
- 年薪
- Michael Rossi
- Director, President and Chief Executive Officer
- 311.06萬
- Thomas Gad
- Vice Chairman of the Board and Chief Business Officer
- 245.45萬
- Vignesh Rajah
- Senior Vice President and Chief Medical Officer
- --
- Joris Wiel Jan Wilms
- Senior Vice President and Chief Operating Officer
- --
- Dr. Torben Lund-Hansen, PhD
- Senior Vice President and Chief Technical Officer
- --
- Sue Smith
- Senior Vice President and Chief Commercial Officer
- 88.73萬
- Peter P. Pfreundschuh
- Chief Financial Officer and Treasurer
- --
- Dr. Steen Lisby
- Senior Vice President and Chief Scientific Officer
- --
- Dr. James I. Healy, M.D.,PhD
- Chairman of the Board
- 18.43萬
- Dr. Mary A. Tagliaferri, M.D.
- Director
- --
- Laura J. Hamill
- Independent Director
- 16.81萬
- Johan Wedell-Wedellsborg
- Independent Director
- 15.81萬
- David N. Gill
- Independent Director
- 18.06萬
- Dr. Ashutosh Tyagi, M.D.
- Independent Director
- 15.81萬
熱議
美股
綜合熱度
股票代碼
最新價
升跌幅
暫無數據